Overexpression of Insulin-Like Growth Factor-Binding Protein-4 (IGFBP-4) in Smooth Muscle Cells of Transgenic Mice through a Smooth Muscle α-Actin-IGFBP-4 Fusion Gene Induces Smooth Muscle Hypoplasia
Insulin-like growth factor I (IGF-I) has been postulated to function as a smooth muscle cell (SMC) mitogen and to play a role in the pathogenesis of bladder hypertrophy, estrogen-induced uterine growth, and restenosis after arterial angioplasty. IGF-binding protein-4 (IGFBP-4) inhibits IGF-I action...
Gespeichert in:
Veröffentlicht in: | Endocrinology (Philadelphia) 1998-05, Vol.139 (5), p.2605-2614 |
---|---|
Hauptverfasser: | , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Insulin-like growth factor I (IGF-I) has been postulated to function as
a smooth muscle cell (SMC) mitogen and to play a role in the
pathogenesis of bladder hypertrophy, estrogen-induced uterine growth,
and restenosis after arterial angioplasty. IGF-binding protein-4
(IGFBP-4) inhibits IGF-I action in vitro and is the most
abundant IGFBP in the rodent arterial wall. To explore the function of
this binding protein in vivo, transgenic mouse lines
were developed harboring fusion genes consisting of a rat IGFBP-4
complementary DNA cloned downstream of either a −724 bp fragment of
the mouse smooth muscle α-actin 5′-flanking region (SMP2-BP-4) or−
1074 bp, 63 bp of 5′-untranslated region, and 2.5 kb of intron 1 of
smooth muscle α-actin (SMP8-BP-4). SMP2-BP-4 mice expressed low
levels of the exogenous IGFBP-4 messenger RNA (mRNA), which was not
specifically targeted to SMC-rich tissue environments, and were
therefore not analyzed further. Six SMP8-BP-4 transgenic lines derived
from separate founders were characterized. Mating of hemizygous
SMP8-BP-4 mice with controls produced about 50% transgenic offspring,
with equal sex distribution. Expression of IGFBP-4 mRNA in
nontransgenic littermates was maximal in liver and kidney. By contrast,
transgenic IGFBP-4 mRNA expression, distinguished because of a smaller
transcript size, was confined to SMC-containing tissues, with the
following hierarchy: bladder > aorta > stomach =
uterus. There was no transgene expression in skeletal muscle, brain, or
cardiac myocytes. The abundance of IGFBP-4 measured by Western ligand
blotting or by immunoblotting, was 8- to 10-fold higher in aorta and
bladder of SMP8-BP-4 mice than in their nontransgenic littermates, with
no change in plasma IGFBP-4 levels. Transgenic mice exhibited a
significant reduction in wet weight of SMC-rich tissues, including
bladder, intestine, aorta, uterus, and stomach, with no change in total
body or carcass weight. In situ hybridization showed
that transgene expression was targeted exclusively to the muscular
layers of the arteries, veins, bladder, ureter, stomach, intestine, and
uterus. Overexpression of IGFBP-4 was associated with SMC hypoplasia, a
reciprocal phenotype to that of transgenic mice overexpressing IGF-I
under control of the same promoter (SMP8-IGF-I). Double transgenic mice
derived from mating SMP8-BP-4 with SMP8-IGF-I animals showed a modest
decrease in wet weight at selected SMC tissues. Although we cannot
exclude that the effects of IGFBP-4 |
---|---|
ISSN: | 0013-7227 1945-7170 |
DOI: | 10.1210/endo.139.5.5986 |